Comparing of Sangamo Therapeutics Inc. (SGMO) and Gossamer Bio Inc. (NASDAQ:GOSS)

This is therefore a contrasting of the analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership in Sangamo Therapeutics Inc. (NASDAQ:SGMO) and Gossamer Bio Inc. (NASDAQ:GOSS). The two are both Biotechnology companies that compete with one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sangamo Therapeutics Inc. 11 16.51 N/A -0.89 0.00
Gossamer Bio Inc. 20 0.00 N/A -2.32 0.00

Demonstrates Sangamo Therapeutics Inc. and Gossamer Bio Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 has Sangamo Therapeutics Inc. and Gossamer Bio Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Sangamo Therapeutics Inc. 0.00% -24.7% -15.3%
Gossamer Bio Inc. 0.00% 0% 0%

Liquidity

Sangamo Therapeutics Inc.’s Current Ratio and Quick Ratio are 4 and 4 respectively. The Current Ratio and Quick Ratio of its competitor Gossamer Bio Inc. are 19.8 and 19.8 respectively. Gossamer Bio Inc. therefore has a better chance of paying off short and long-term obligations compared to Sangamo Therapeutics Inc.

Analyst Recommendations

Sangamo Therapeutics Inc. and Gossamer Bio Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Sangamo Therapeutics Inc. 0 1 0 2.00
Gossamer Bio Inc. 0 0 0 0.00

The upside potential is 1.38% for Sangamo Therapeutics Inc. with average target price of $11.

Insider and Institutional Ownership

Sangamo Therapeutics Inc. and Gossamer Bio Inc. has shares owned by institutional investors as follows: 58.7% and 72.1%. Insiders owned roughly 0.2% of Sangamo Therapeutics Inc.’s shares. Comparatively, 1.1% are Gossamer Bio Inc.’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sangamo Therapeutics Inc. 0.5% 13.41% 5.54% 3.62% -8.32% 4.62%
Gossamer Bio Inc. 6.95% -11.66% 19.08% 0% 0% 10.65%

For the past year Sangamo Therapeutics Inc.’s stock price has smaller growth than Gossamer Bio Inc.

Summary

Gossamer Bio Inc. beats on 5 of the 8 factors Sangamo Therapeutics Inc.

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The companyÂ’s proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and with Shire International GmbH to develop the preclinical development program in HuntingtonÂ’s disease, as well as license agreement with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.